# DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award

Source: https://welltoldgrants.com/grants/ht942526dmdrpctra-dow-duchenne-muscular-dystrophy-clinical-translational/  
Official notice: https://www.grants.gov/search-results-detail/362851

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 6 awards worth $8.5 million in total. Applications closed on September 18, 2026.

| Field | Value |
|---|---|
| Opportunity number | HT942526DMDRPCTRA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 18, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 6 |
| Total funding | $8.5 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged. Distinctive Features: The FY26 CTRA offers two funding levels: • Funding Level 1 to support smaller, less complex preclinical and/or clinical research. • Funding Level 2 to support larger, more complex preclinical and/or clinical research. The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories: • Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. • Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field. Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed.

## Questions people ask

### Is HT942526DMDRPCTRA still open?

No. It closed on September 18, 2026. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award?

Closed September 18, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $8.5 million in total across about 6 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.